Evidence map›Paper›PMID 29682213›Full record

ArticleOncotarget2018

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

Yoshiaki Yamamoto, Ryouichi Tsunedomi, Yusuke Fujita, Toru Otori, Mitsuyoshi Ohba, Yoshihisa Kawai, Hiroshi Hirata, Hiroaki Matsumoto, Jun Haginaka, Shigeo Suzuki and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yoshiaki YamamotoDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Ryouichi TsunedomiDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
Yusuke FujitaDepartment of Computer Science and Systems Engineering, Yamaguchi University Graduate School of Sciences and Technology for Innovation, Ube, Yamaguchi, Japan.
Toru OtoriFaculty of Pharmacy, Kindai University, Higashiosaka, Osaka, Japan.
Mitsuyoshi OhbaTechnical Research Laboratory, Toyo Kohan Company Ltd., Kudamatsu, Yamaguchi, Japan.
Yoshihisa KawaiDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Hiroshi HirataDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Hiroaki MatsumotoDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Jun HaginakaSchool of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, Japan.
Shigeo SuzukiDepartment of Laboratory of Analytical Chemistry for Pharmaceutical Sciences, Kindai University, Higashiosaka, Osaka, Japan.
Rajvir DahiyaDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California at San Francisco, San Francisco, California, USA.
Yoshihiko HamamotoDepartment of Computer Science and Systems Engineering, Yamaguchi University Graduate School of Sciences and Technology for Innovation, Ube, Yamaguchi, Japan.
Kenji MatsuyamaFaculty of Pharmacy, Daiichi College of Pharmaceutical Sciences, Fukuoka, Fukuoka, Japan.
Shoichi HazamaDepartment of Translational Research and Developmental Therapeutics Against Cancer, Yamaguchi University Faculty of Medicine, Ube, Yamaguchi, Japan.
Hiroaki NaganoDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
Hideyasu MatsuyamaDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the relationship between axitinib pharmacogenetics and clinical efficacy/adverse events in advanced renal cell carcinoma (RCC) and established a model to predict clinical efficacy and adverse events using pharmacokinetic and gene polymorphisms related to drug metabolism and efflux in a phase II trial. We prospectively evaluated the area under the plasma concentration-time curve (AUC) of axitinib, objective response rate, and adverse events in 44 consecutive advanced RCC patients treated with axitinib. To establish a model for predicting clinical efficacy and adverse events, polymorphisms in genes including ABC transporters (

Indexed as

area under the plasma concentration–time curveaxitinibgene polymorphismspharmacogeneticsrenal cell carcinoma

Identifiers

PMID29682213
PMCPMC5908314

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.